HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cranford, R. E. Articles by Kostick, B. Search for Related Content PubMed PubMed Citation Articles by Cranford, R. E. Articles by Kostick, B.

Intravenous phenytoin

Clinical and pharmacokinetic aspects

Department of Neurology, University of Minnesota School of Medicine, and the Departments of Neurology, Hennepin County Medical Center (Dr. Cranford), and St. Paul-Ramsey Hospital (Dr. Leppik).

Phenytoin was administered intravenously in large doses (mean = 16.6 mg per kilogram) for prevention and treatment of seizures on 159 occasions to 139 patients aged 17 to 94 years (mean = 52 years) and weighing 37 to 113 kg (mean = 65 kg). Hypotension was more frequent among older patients. No deaths were attributable to phenytoin. Volumes of distribution were relatively constant (mean = 0.78 ± 0.11 liters per kilogram), but half-lives varied considerably and were prolonged (mean = 51 ± 32 hours) because of the large doses administered. A dose of 18 mg per kilogram was effective in maintaining phenytoin serum levels above 10 pg per milliliter for 24 hours.

Reprint requests should be addressed to Dr. Cranford, Department of Neurology, Hennepin County Medical Center, 701 Park Avenue So., Minneapolis, MN 55415.

Supported by NINDS Contract No. N01-NS-5-2327.

This work was presented in part at the twenty-ninth annual meeting of the American Academy of Neurology, April 1977, Atlanta, Georgia.

Accepted for publication February 15, 1978.

This article has been cited by other articles:

				U. Idrees and M. Londner Pharmacotherapy Overview of Seizure Management in the Adult Emergency Department Journal of Pharmacy Practice, October 1, 2005; 18(5): 394 - 411. [Abstract] [PDF]

				R E Appleton and C Demellweek Post-traumatic epilepsy in children requiring inpatient rehabilitation following head injury J. Neurol. Neurosurg. Psychiatry, May 1, 2002; 72(5): 669 - 672. [Abstract] [Full Text] [PDF]

				T. J. O'Brien, F. M. Meara, H. Matthews, and F. J. Vajda Prospective study of local cutaneous reactions in patients receiving IV phenytoin Neurology, October 23, 2001; 57(8): 1508 - 1510. [Abstract] [Full Text] [PDF]

				P. D. Meek, S. N. Davis, D. M. Collins, B. E. Gidal, P. A. Rutecki, A. H. Burstein, J. H. Fischer, I. E. Leppik, R. E. Ramsay, and for the Panel on Nonemergency Use of Parenteral Ph Guidelines for Nonemergency Use of Parenteral Phenytoin Products: Proceedings of an Expert Panel Consensus Process Arch Intern Med, December 13, 1999; 159(22): 2639 - 2644. [Abstract] [Full Text] [PDF]

				W. M. Coplin, D. H. Rhoney, E. A. Lyons, K. R. Murry, T. J. O'Brien, G. D. Cascino, E. L. So, D. R. Hanna Rochester MN, and T. R. Browne Incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin Neurology, October 22, 1999; 53(7): 1611 - 1611. [Full Text]

				D. H. Lowenstein and B. K. Alldredge Status Epilepticus N. Engl. J. Med., April 2, 1998; 338(14): 970 - 976. [Full Text] [PDF]